Suppr超能文献

聚酯酰胺微球平台释放的曲安奈德对骨关节炎炎症的长期抑制作用。

Prolonged inhibition of inflammation in osteoarthritis by triamcinolone acetonide released from a polyester amide microsphere platform.

机构信息

Department of Orthopaedics, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.

DSM Biomedical, Koestraat 1, 6167 RA Geleen, The Netherlands.

出版信息

J Control Release. 2017 May 10;253:64-72. doi: 10.1016/j.jconrel.2017.03.014. Epub 2017 Mar 9.

Abstract

Controlled biomaterial-based corticosteroid release might circumvent multiple injections and the accompanying risks, such as hormone imbalance and muscle weakness, in osteoarthritic (OA) patients. For this purpose, microspheres were prepared from an amino acid-based polyester amide (PEA) platform and loaded with triamcinolone acetonide (TAA). TAA loaded microspheres were shown to release TAA for over 60days in PBS. Furthermore, the bioactivity lasted at least 28days, demonstrated by a 80-95% inhibition of PGE production using TNFα-stimulated chondrocyte culture, indicating inhibition of inflammation. Microspheres loaded with the near infrared marker NIR780-iodide injected in healthy rat joints or joints with mild collagenase-induced OA showed retention of the microspheres up till 70days after injection. After intra-articular injection of TAA-loaded microspheres, TAA was detectable in the serum until day seven. Synovial inflammation was significantly lower in OA joints injected with TAA-loaded microspheres based on histological Krenn scores. Injection of TAA-loaded nor empty microspheres had no effect on cartilage integrity as determined by Mankin scoring. In conclusion, the PEA platform shows safety and efficacy upon intra-articular injection, and its extended degradation and release profiles compared to the currently used PLGA platforms may render it a good alternative. Even though further in vivo studies may need to address dosing and readout parameters such as pain, no effect on cartilage pathology was found and inflammation was effectively lowered in OA joints.

摘要

控制生物材料的皮质类固醇释放可能会避免多次注射和随之而来的风险,如激素失衡和肌肉无力,在骨关节炎(OA)患者中。为此,采用氨基酸为基础的聚酯酰胺(PEA)平台制备了微球,并负载三醋酸曲安奈德(TAA)。研究表明,TAA 负载的微球在 PBS 中可以释放 TAA 超过 60 天。此外,生物活性至少持续 28 天,这是通过 TNFα 刺激的软骨细胞培养物抑制 PGE 产生达到 80-95%来证明的,表明抑制了炎症。在健康大鼠关节或轻度胶原酶诱导的 OA 关节中注射负载近红外标记物 NIR780-碘化物的微球,在注射后 70 天内仍可保留微球。在关节内注射 TAA 负载的微球后,在第 7 天之前可在血清中检测到 TAA。根据 Krenn 评分,OA 关节中注射 TAA 负载的微球后,滑膜炎症明显降低。注射 TAA 负载的微球和空微球对软骨完整性没有影响,这是通过 Mankin 评分来确定的。总之,PEA 平台在关节内注射时表现出安全性和疗效,与目前使用的 PLGA 平台相比,其延长的降解和释放特性可能使其成为一种良好的替代品。尽管进一步的体内研究可能需要解决剂量和读出参数,如疼痛,但在 OA 关节中没有发现对软骨病理的影响,并且炎症得到了有效降低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验